Jay Schneider, PhD

Adjunct Professor of Pharmacology
Department: Systems Pharmacology and Translational Therapeutics
Contact information
Thomas Jefferson University
Department of Pathology, Anatomy and Cell Biology
1020 Locust Street, JAH 521
Philadelphia, PA 19107
Department of Pathology, Anatomy and Cell Biology
1020 Locust Street, JAH 521
Philadelphia, PA 19107
Education:
B.A. (Psychology)
State University of New York, Stony Brook, 1977.
Ph.D. (Psychology)
State University of New York, Stony Brook, 1981.
Permanent linkB.A. (Psychology)
State University of New York, Stony Brook, 1977.
Ph.D. (Psychology)
State University of New York, Stony Brook, 1981.
Selected Publications
Schneider, J.S: A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson’s disease. Gylcoconjugate Journal 2021 Notes: https://doi.org/10.1007/s10719-021-10002-2.Schneider, J.S., Marshall, C.A., Keibel, L., Snyder, N.W., Hill, M.P., Brotchie, J.M., Johnston, T.H., Waterhouse, B., and Kortagere, S.: A novel Dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease. Experimental Neurology 2021 Notes: https://doi.org/10.1016/j.expneurol.2020.113514.
Barth, A.L., Schneider, J.S., Johnston, T.H., Hill, M.P., Brotchie, J.M., Moskal, J.R., Cearley, C.N.: NYX-458 improves cognitive performance in a primate Parkinson’s disease model. Movement Disorders January 2020 Notes: https://doi.org/10.1002/mds.27962.
Neuwirth, L.S., Lopez, O.E., Schneider, J.S. and Markowitz, M.E.: Low-level lead exposure impairs fronto-executive functions: A call to update the DSM-V with lead poisoning as a neurodevelopmental disorder. Journal of Psychology & Neuroscience, 2020 Notes: https://doi.org/10.1037/pne0000225.
Magistretti, P.J., Geisler, F.H., Schneider, J.S., Li, A., Fiumelli, H., Sipione, S.: Gangliosides: Treatment avenues in neurodegenerative disease. Frontiers Neurology August 2019 Notes: doi: 10.3389/fneur.2019.00859.
Verma Megha, Schneider Jay S: siRNA-mediated knockdown of B3GALT4 decreases GM1 ganglioside expression and enhances vulnerability for neurodegeneration. Molecular and cellular neurosciences 95: 25-30, Jan 2019.
Schneider, J.S., Aras, R., Williams, C.K., Koprich, J.B., Brotchie, J.M., and Singh, V.: GM1 ganglioside modifies a-synuclein toxicity and is neuroprotective in a rat asynuclein model of Parkinson’s disease. Nature - Scientific Reports 2019 Notes: https://doi.org/10.1038/s41598-019-42847-x.
Guilarte, T.R., Yeh, C.-L., McGlothan, J.L., Perez, J., Finley, P., Zhou, Y., Wong, D.F.,Dydak, U., and Schneider, J.S.: PET imaging of dopamine release in the frontal cortex of manganese-exposed non-human primates. J. Neurochemistry 150(2): 188-201, 2019.
Singh, V., Aras, R., Singh, G., Schneider, J.S: M1 ganglioside as a modifier of alphasynuclein toxicity in vivo and in cell culture. Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, Online.(Program No. 213.08), 2019.
Schneider, J.S., Singh, V.: Dysregulation of sphingolipid expression and metabolism and its role in the pathogenesis of Parkinson's disease. Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience. Online(Program No. 213.01), 2019.